07
078160.KQ MEDIPOST Co. Ltd
- Market cap
- KRW 316B
- P/E
- -
- P/B
- 1.16x
- ROE
- 15.9%
- Dividend yield
- -
- Fundamental score
- 1.8/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 078160.KQ undervalued?
Graham numberThe Graham number of MEDIPOST Co. Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
MEDIPOST Co. Ltd fundamental analysis
9 of 22 checks passedROE 1/2
Moderate return on equity (15.9%), between 10% and 20%.
ROA 1/1
Return on assets (7.8%) is above the industry median (-1.2%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share did not grow over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 1/1
Last year's EPS growth (-19.2%) is above the industry median (-108.1%).
Revenue Growth 1/2
Revenue grew 4.7% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (3.7%), 40% or less.
Debt Trend 1/1
Debt to equity has not risen over the past 5 years.
Debt Coverage 0/1
Operating cash flow does not cover 20% of total debt.
Interest Coverage 0/1
EBIT is 2.3x against interest expense, below 5x.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 1/1
Price to book (1.2x) is below the industry median (1.2x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
MEDIPOST Co. Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About MEDIPOST Co. Ltd
MEDIPOST Co., Ltd. provides stem cell therapeutic solutions to meet the unmet medical needs in South Korea and internationally. It operates CELLTREE, an umbilical cord blood bank; and offers cord blood banking services to treat various incurable diseases. The company also markets CARTISTEM for the treatment of repetitive and/or traumatic cartilage degeneration, including degenerative osteoarthritis. In addition, it is developing stem cell drugs, such as PNEUMOSTEM, which is …
Full company profileMEDIPOST Co. Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
MEDIPOST Co. Ltd annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 28.7B | 42.2B | 44.4B | 45.8B | 48.6B | 54.9B | 64.2B | 68.6B | 70.7B | 73.7B | 76.5B |
| Gross Profit | 15.7B | 25.2B | 28.4B | 29.0B | 30.9B | 31.9B | 38.4B | 40.2B | 44.1B | 45.4B | 50.2B |
| Operating Income | -10.0B | -4.68B | -6.59B | -8.20B | -2.41B | -3.37B | -20.2B | 5.07B | -66.0B | -68.0B | -82.4B |
| EBITDA | - | - | - | - | - | - | 20.2B | 16.7B | -56.4B | -79.4B | 54.4B |
| Net Income | -5.37B | -950M | -2.01B | -14.1B | -1.90B | -683M | 3.07B | 5.84B | -62.5B | -85.4B | 43.5B |
| EPS | -347 | -61 | -129 | -911 | -122 | -42 | 190 | 171 | -1,834 | -2,185 | 1,114 |
| Balance Sheet | |||||||||||
| Total Assets | 179B | 145B | 176B | 214B | 220B | 254B | 398B | 449B | 414B | 432B | 559B |
| Total Liabilities | 36.0B | 40.2B | 48.9B | 102B | 103B | 94.6B | 218B | 136B | 162B | 182B | 285B |
| Shareholders' Equity | 143B | 104B | 127B | 112B | 117B | 159B | 180B | 312B | 251B | 249B | 273B |
| Cash & Short-term Investments | 24.1B | 20.6B | 35.2B | 64.5B | 56.5B | 56.3B | 122B | 37.5B | 32.7B | 76.9B | 78.4B |
| Total Debt | 15.6B | 15.6B | - | 35.3B | 10.3B | - | - | - | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -12.4B | -6.93B | 6.89B | 7.51B | 1.78B | 4.06B | -6.19B | -19.1B | -37.3B | -57.1B | -59.6B |
| Capital Expenditure | 9.93B | 788M | 1.29B | 9.31B | 7.85B | 10.2B | 3.56B | 2.61B | 3.26B | 3.28B | 5.91B |
| Free Cash Flow | - | - | - | -4.17B | -6.28B | -6.65B | -9.75B | -21.7B | -40.5B | -60.4B | -65.5B |
| Ratios | |||||||||||
| ROE | -3.7% | -0.9% | -1.6% | -12.7% | -1.6% | -0.4% | 1.7% | 1.9% | -24.9% | -34.3% | 15.9% |
| ROA | -3.0% | -0.7% | -1.1% | -6.6% | -0.9% | -0.3% | 0.8% | 1.3% | -15.1% | -19.8% | 7.8% |
| Net Profit Margin | -18.7% | -2.2% | -4.5% | -30.8% | -3.9% | -1.2% | 4.8% | 8.5% | -88.5% | -115.9% | 56.9% |
| Debt to Equity | 0.11x | 0.15x | - | 0.32x | 0.09x | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
MEDIPOST Co. Ltd dividends
MEDIPOST Co. Ltd has not paid dividends in the last 9 fiscal years.
Last stock split: 339:298 on Sep 19, 2023.
Who owns MEDIPOST Co. Ltd
- Insiders 16.92%
- Institutions 5.42%
- Public & others 77.67%
- Shares outstanding 15.4M
- Free float 12.7M
MEDIPOST Co. Ltd company profile
- Company name
- MEDIPOST Co. Ltd
- Ticker
- 078160.KQ
- ISIN
- KR7078160009
- Exchange
- KOSDAQ
- Listed since
- Jul 29, 2005
- Sector
- Healthcare
- Industry
- Health Care Providers & Services
- Employees
- 271
- Fiscal year end
- December
- Address
- 21, Daewangpangyo-ro, Seongnam-si, South Korea
- Phone
- 82 2 3465 6677
- Website
- medi-post.co.kr
About MEDIPOST Co. Ltd
MEDIPOST Co., Ltd. provides stem cell therapeutic solutions to meet the unmet medical needs in South Korea and internationally. It operates CELLTREE, an umbilical cord blood bank; and offers cord blood banking services to treat various incurable diseases. The company also markets CARTISTEM for the treatment of repetitive and/or traumatic cartilage degeneration, including degenerative osteoarthritis. In addition, it is developing stem cell drugs, such as PNEUMOSTEM, which is in completed Phase II clinical trial in South Korea, as well as in Phase I/II clinical trial in the United States for the preventative treatment of bronchopulmonary dysplasia; and NEUROSTEM that is in Phase I/IIa clinical study to treat Alzheimer's disease. Further, the company develops SMUP-IA-01, which has completed phase I clinical trial for the treatment of osteoarthritis; and SMUP-IV-01 for the treatment of diabetic nephropathy, as well as offers nutritional and dietary supplements under the MOVITA brand name. MEDIPOST Co., Ltd. was founded in 2000 and is headquartered in Seongnam, South Korea.
MEDIPOST Co. Ltd management
7- Dr. Won-II Oh M.D., Ph.D.Gen. Director of Laboratory, VP and Director · born 1962
- Mr. Jang-Won LeeSr. Managing Director and Exec. Director · born 1966
- Dr. Yoon-Seon YangCEO & Pres · born 1964
- Dr. Sung-Ho Han Ph.D.Head Mang. of Bus. Devel. Division and Director · born 1970
- Dr. Soo-Jin Choi M.D., Ph.D.Director of Research Department and Director · born 1971
- Mr. Young-Hwan SongHead Mang. of Management Support Division and Director · born 1966
- Ms. Hye-Kyung HongDirector of 1st Research Department and Director · born 1969